Steinbrenner, Mirja http://orcid.org/0000-0001-5425-4709
Tito, Tabea http://orcid.org/0000-0003-0922-3780
Dehnicke, Christoph
Holtkamp, Martin http://orcid.org/0000-0003-2258-1670
Funding for this research was provided by:
Berlin Institute of Health
v. Bodelschwingh Foundation Bethel
Charité - Universitätsmedizin Berlin
Article History
Received: 19 September 2022
Revised: 24 November 2022
Accepted: 28 November 2022
First Online: 6 December 2022
Declarations
:
: MH reports personal fees as speaker and consultant within the last 3 years from Angelini/Arvelle, Bial, Desitin, Eisai, GW Pharma, Neuraxpharm, UCB, and Zogenix outside the submitted work. The other authors have no conflicts of interest.
: This prospective study was approved by the ethics committee of Charité–Universitätsmedizin Berlin (EA1/293/15). All included patients signed their consent to participate. The study conforms to World Medical Association Declaration of Helsinki.